Now that Remdesivir is approved by the FDA, should we be billing this drug with HCPCS code C9399?

On October 22, 2020, the FDA did issue an approval for Remdesivir; this means that the drug does meet the HCPCS definition of code C9399. However, it is important to point out that the FDA approval still reserves the use of Remdesivir for only those patients requiring inpatient hospital care. With the exception of hemophilia clotting factors, neither revenue code 636 or drug HCPCS codes are reported on inpatient claims.  From a chargemaster perspective, it is likely not necessary to assign HCPCS C9399 to your charges for Remdesivir as this HCPCS code will not be reported on your corresponding inpatient claims.

FDA Approval Notification for Remdesivir:
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19